The following table provides revenues by product: | ||||||||||||
Year Ended December 31, | ||||||||||||
(MILLIONS OF DOLLARS) | 2013 | 2012 | 2011(a) | |||||||||
Revenues from biopharmaceutical products: | ||||||||||||
Lyrica | $ | 4,595 | $ | 4,158 | $ | 3,693 | ||||||
Prevnar family | 3,974 | 4,117 | 4,145 | |||||||||
Enbrel (Outside the U.S. and Canada) | 3,774 | 3,737 | 3,666 | |||||||||
Celebrex | 2,918 | 2,719 | 2,523 | |||||||||
Lipitor(b) | 2,315 | 3,948 | 9,577 | |||||||||
Viagra | 1,881 | 2,051 | 1,981 | |||||||||
Zyvox | 1,353 | 1,345 | 1,283 | |||||||||
Norvasc | 1,229 | 1,349 | 1,445 | |||||||||
Sutent | 1,204 | 1,236 | 1,187 | |||||||||
Premarin family | 1,092 | 1,073 | 1,013 | |||||||||
BeneFIX | 832 | 775 | 693 | |||||||||
Vfend | 775 | 754 | 747 | |||||||||
Genotropin | 772 | 832 | 889 | |||||||||
Pristiq | 698 | 630 | 577 | |||||||||
Chantix/Champix | 648 | 670 | 720 | |||||||||
Refacto AF/Xyntha | 602 | 584 | 506 | |||||||||
Xalatan/Xalacom | 589 | 806 | 1,250 | |||||||||
Detrol/Detrol LA | 562 | 761 | 883 | |||||||||
Zoloft | 469 | 541 | 573 | |||||||||
Medrol | 464 | 523 | 510 | |||||||||
Effexor | 440 | 425 | 678 | |||||||||
Zosyn/Tazocin | 395 | 484 | 636 | |||||||||
Zithromax/Zmax | 387 | 435 | 453 | |||||||||
Fragmin | 359 | 381 | 382 | |||||||||
Relpax | 359 | 368 | 341 | |||||||||
Tygacil | 358 | 335 | 298 | |||||||||
Rapamune | 350 | 346 | 372 | |||||||||
Inlyta | 319 | 100 | — | |||||||||
Sulperazon | 309 | 262 | 218 | |||||||||
Revatio | 307 | 534 | 535 | |||||||||
Cardura | 296 | 338 | 380 | |||||||||
Xalkori | 282 | 123 | 16 | |||||||||
Xanax/Xanax XR | 276 | 274 | 306 | |||||||||
Diflucan | 242 | 259 | 265 | |||||||||
Toviaz | 236 | 207 | 187 | |||||||||
Aricept(c) | 235 | 326 | 450 | |||||||||
Inspra | 233 | 214 | 195 | |||||||||
Caduet | 223 | 258 | 538 | |||||||||
Somavert | 217 | 197 | 183 | |||||||||
Neurontin | 216 | 235 | 289 | |||||||||
Unasyn | 212 | 228 | 231 | |||||||||
BMP2 | 209 | 263 | 340 | |||||||||
Geodon | 194 | 353 | 1,022 | |||||||||
Depo-Provera | 191 | 148 | 139 | |||||||||
Aromasin | 185 | 210 | 361 | |||||||||
Xeljanz | 114 | 6 | — | |||||||||
Alliance revenues(d) | 2,628 | 3,492 | 3,630 | |||||||||
All other biopharmaceutical products | 7,360 | 7,804 | 7,441 | |||||||||
Total revenues from biopharmaceutical products | 47,878 | 51,214 | 57,747 | |||||||||
Other revenues: | ||||||||||||
Consumer Healthcare | 3,342 | 3,212 | 3,028 | |||||||||
Other(e) | 364 | 231 | 260 | |||||||||
Revenues | $ | 51,584 | $ | 54,657 | $ | 61,035 | ||||||
(a) | For 2011, includes King commencing on the acquisition date of January 31, 2011. |
(b) | Lipitor lost exclusivity in Australia in April 2012, most of developed Europe in March and May 2012, the U.S. in November 2011 and various other major markets in 2011 and 2012. This loss of exclusivity reduced branded worldwide revenues by $1.7 billion in 2013, in comparison with 2012, and reduced branded worldwide revenues by $5.6 billion in 2012, in comparison with 2011. |
(c) | Represents direct sales under license agreement with Eisai Co., Ltd. |
(d) | Includes Enbrel (in the U.S. and Canada through October 31, 2013), Spiriva, Rebif, Aricept and Eliquis. |
(e) | Other represents revenues generated from Pfizer CentreSource, our contract manufacturing and bulk pharmaceutical chemical sales organization, and includes, in 2013, the revenues related to our transitional manufacturing and supply agreements with Zoetis. |